Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP3555)
Name
Evodiamine
Synonyms
Evodiamine; 518-17-2; d-Evodiamine; (+)-Evodiamine; UNII-C01825BVNL; C01825BVNL; CHEBI:4948; Evodiamine, 98%; (S)-14-methyl-8,13,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one; Evodiamine, Evodia rutaecarpa; PubChem18244; Evodiamine, (+)-; Evodiamine,(S); (13bS)-14-methyl-8,13,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one; Evodiamine(Isoevodiamine)/; MLS006011787; SCHEMBL682158; CHEMBL463165; DTXSID10966123; ZINC898159; BCP02282; HY-N0114; ABP000693; BBL033833; STK801981; AKOS005622478; CS-6161; MCULE-2788564607; (S)-14-methyl-7,8,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(13H)-one; SMR001934404; VS-12304; N1600; C09187; 518E172; Q-100579; Q27894193; Evodiamine, European Pharmacopoeia (EP) Reference Standard; 14-Methyl-8,13,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one; (1S)-21-METHYL-3,13,21-TRIAZAPENTACYCLO[11.8.0.0(2),(1)?.0?,?.0(1)?,(2)?]HENICOSA-2(10),4,6,8,15,17,19-HEPTAEN-14-ONE; (1S)-21-methyl-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,15,17,19-heptaen-14-one; Indol(2',3':3,4)pyrido(2,1-b)quinazolin-5(7H)-one, 8,13,13b,14-tetrahydro-14-methyl-, (13bS)-; Indol(2',3':3,4)pyrido(2,1-b)quinazolin-5(7H)-one, 8,13,13b,14-tetrahydro-14-methyl-, (S)-
    Click to Show/Hide
Species Origin Evodia rutaecarpa Bentham ...     Click to Show/Hide
Evodia rutaecarpa Bentham
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Sapindales
Family: Rutaceae
Genus: Tetradium
Species: Evodia rutaecarpa Bentham
Disease Lung cancer [ICD-11: 2C25] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H17N3O
PubChem CID
442088
Canonical SMILES
CN1C2C3=C(CCN2C(=O)C4=CC=CC=C41)C5=CC=CC=C5N3
InChI
1S/C19H17N3O/c1-21-16-9-5-3-7-14(16)19(23)22-11-10-13-12-6-2-4-8-15(12)20-17(13)18(21)22/h2-9,18,20H,10-11H2,1H3/t18-/m0/s1
InChIKey
TXDUTHBFYKGSAH-SFHVURJKSA-N
CAS Number
CAS 518-17-2
ChEBI ID
CHEBI:4948
Herb ID
HBIN026264
SymMap ID
SMIT01413
TCMSP ID
MOL003958
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          TNF-related apoptosis inducing ligand      Lung cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression CTNNB1  Molecule Info 
Pathway MAP
                    In-vitro Model U-87MG ATCC CVCL_0022 Glioblastoma Homo sapiens
                    Experimental
                    Result(s)
Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway.
Target and Pathway
Target(s) Transient receptor cation channel V1 (TRPV1)  Molecule Info  [3]
KEGG Pathway Neuroactive ligand-receptor interaction Click to Show/Hide
2 Inflammatory mediator regulation of TRP channels
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
Pathway Interaction Database Trk receptor signaling mediated by the MAPK pathway Click to Show/Hide
2 Trk receptor signaling mediated by PI3K and PLC-gamma
Reactome TRP channels Click to Show/Hide
References
Reference 1 Evodiamine suppresses non-small cell lung cancer by elevating CD8 + T cells and downregulating the MUC1-C/PD-L1 axis. J Exp Clin Cancer Res. 2020 Nov 19;39(1):249.
Reference 2 Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway. Mol Med Rep. 2015 Jan;11(1):257-62.
Reference 3 Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis. Acta Physiol (Oxf). 2013 Feb;207(2):299-307.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China